In vitro selection of Plasmodium falciparum drug-resistant parasite lines by Nzila, Alexis & Mwai, Leah
In vitro selection of Plasmodium falciparum drug-resistant
parasite lines
Alexis Nzila1,2* and Leah Mwai1,2
1Kenya Medical Research Institute (KEMRI)/Wellcome Trust Collaborative Research Program, PO Box 230, 80108 Kiliﬁ, Kenya;
2University of Oxford, Nufﬁeld Department of Medicine, John Radcliffe Hospital, Oxford, UK
*Corresponding author. Tel: þ254-417-522-535; Fax: þ254-417-522-290; E-mail: anzila@kiliﬁ.kemri-wellcome.org
The in vitro selection of antimicrobial resistance in important pathogens can provide critical information on the
genetic basis of drug resistance, and such information can be used to predict, anticipate and even contain the
spread of resistance in clinical practice. For instance, the discovery of the role of pfmdr1 in meﬂoquine resist-
ance in malaria parasites resulted from in vitro studies. However, the in vitro selection of resistance is difﬁcult,
challenging and time consuming. In this review, we discuss the key parameters that impact on the efﬁciency of
the in vitro selection of resistance, and propose strategies to improve and streamline this process.
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Introduction
The control of malaria rests on the use of mosquito vector
control and antimalarial chemotherapy. However, the latter
strategy is hampered by the emergence of antimalarial resist-
ance. Currently, there is no antimalarial drug that malaria
parasites have not developed resistance against. Worryingly,
there is evidence that malaria parasites in Cambodia are becom-
ing resistant to artemisinin derivatives,
1 providing a potential
threat to artemisinin-based combination therapy (ACT), the
cornerstone of current treatment. This emphasizes the need to
reduce drug resistance selection pressure by withdrawing mono-
therapies,
2 to develop new and affordable drug combinations,
and to understand the mechanisms that underlie resistance to
existing antimalarials. This could lead to: (i) the development
of simple means of tracking the selection and spread of resist-
ance; and (ii) the design and discovery of new and more
potent antimalarials.
To study mechanisms of resistance, one needs to obtain well-
characterized drug-resistant strains. However, such strains are
not generally available for most antimalarials. Murine malaria—
Plasmodium berghei, Plasmodium chabaudi, Plasmodium yeolii
and Plasmodium vinckei—have been used as surrogates for
Plasmodium falciparum to study the mechanisms of drug
resistance by inducing resistance in vivo. This approach has led to
the selection of drug-resistant parasite lines and subsequent
studies on mechanisms of drug resistance.
3 However, for drugs
such as chloroquine and probably artemisinin, mechanisms of
resistance in murine and P. falciparum malaria are different,
highlighting the limitations of the murine malaria model.
4–8
The development of the in vitro system for the routine culture
of P. falciparum in 1976 provided a tool to induce resistance
in vitro.
9 In 1978, Nguyen-Dinh and Trager
10 reported for the
ﬁrst time the selection of chloroquine resistance in vitro. This
study heralded a new era and showed that selection of anti-
malarial resistance could be achieved in vitro in P. falciparum,
thus permitting the study of the mechanisms of antimalarial
resistance even before drugs were used in clinical practice.
While this approach has been used to select some drug-resistant
strains (see Table 1), it has not yet been used to study most of
the antimalarials that are either in clinical use, such as the arte-
misinin derivatives, lumefantrine and piperaquine, or drugs in the
pipeline and likely to be used in the near future, such as tafeno-
quine and pyronaridine.
1,11–13
Among these drugs, artemisinins are the most important.
Indeed, this drug family is currently the backbone of malaria
therapy as they form the basis of ACTs, and artesunate is replacing
quinine inthe treatment of severe malaria.
14–16A majorconcern is
that resistance to this drug family is now emerging in South East
Asia. Strategies are being put in place to predict, control and
contain the emergence of artemisinin resistance.
1,17 These strat-
egies would be enhanced if the mechanism of resistance was
identiﬁed and a simple marker developed for epidemiological
studies. PfATPase6 has been proposed as the molecular target
and polymorphisms have been associated with artemether resist-
ance,
18 but thishas not been conﬁrmed elsewhere.
1 Consequently,
in the absence of well-characterized drug-resistant strains, the
mechanism of artemisinin resistance still awaits characterization.
Could the in vitro culture system permit the selection of stable
resistant parasites to these important antimalarials?
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390Table 1. Summary of main ﬁndings of in vitro selection of resistance to antimalarials in P. falciparum strains
Drugs Strains (drug resistance proﬁle
a)R i
c (IC50)
Ratio of
HDC
d
per IC50
after
drug
pressure
Time
required
to select
resistance
(months)
Stability: period of
drug-free culture
(months) Work carried out on parasite lines: main ﬁnding Ref.
CQ FCR3 (CQ and CG resistant) NM NM 4 1 NM 10
FAC8 (CQ resistant) 2.34 (83 ng/mL) 1.23 NM 1 deampliﬁcation of pfmdr1 in association with CQ
resistance
34
HB3 (PM resistant) 1.64 (28 ng/mL) 1.74 30 NM DNA ampliﬁcation in chromosomes 3 and 12;
deampliﬁcation in chromosome 3 after drug
removal
39
106/01 (CQ susceptible)
b 12 (37 nM) 0.23 2 NM evidence that the presence of pre-existing
mutations in pfcrt lead to a rapid selection of
the key 76 mutation
38
MFQ FCK (CQ resistant) 16 (8 nmol/L) 0.5 3 NM NM 27
Smith (CQ, PM and SD resistant) 3.4 (3.5 mg/L) inverse relationship between MFQ and CQ 28
Camp (CQ susceptible) 2.4 (4.9–12 mg/L) 1.66 .1
e 6 and cryopreservation
W2 (CQ, PM and SD resistant) 4.6 (4.5 nM) 1.93 22.4 12 1. inverse relationship between CQ and MFQ
activity
21
2. identiﬁcation of pfmdr1 as MFQ resistance
marker
K1 (CQ, PM and SD resistant) 4.07 (22.4 ng/mL) 0.8 NM NM 1. MFQ resistance associated with pfmdr1
overampliﬁcation
29
W2mef (CQ, PM, SD and MFQ resistant) 1.41 (58.88 ng/mL) 1.08 NM NM 2. evidence of inverse relationship with CQ
W2mef (CQ, PM, SD and MFQ resistant) 1.07 (15.2 ng/mL) 148.1 18 NM evidence of cross-resistance with HFT and QN and
inverse relationship with CQ
26
HFT T9.96 (CQ susceptible) 3.3 (6.6–22 nM) 0.45 6 6 and cryopreservation cross-resistance with QN but inverse relationship
with CQ
71
K1 (CQ and SD resistant) 9 (2.2 nM) 0.4 2
PM FCR3 NM (15 nM) NM 7 DNA ampliﬁcation (chromosome containing dhfr
f)4 0
5FO W2 100 (2 nM) 1 2 NM evidence that resistance emerges quicker in
already resistant strains
63
FCR3 NM 1 2 NM
ATV W2 30 (3 nM) 1.1 2 NM evidence that resistance emerges quicker in
already resistant strains
63
K1 837 (13.6 nM) 1.6 NM ,3 evidence that mutations in cytochrome b are
associated with ATV resistance
46
BMS-3888891 Dd2 (CQ, QN, PM and SD resistant) 12 (10 nM) NM 2.66 NM evidence that resistance is associated with point
mutation in protein farnesyl transferase
51
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CThe selection of in vitro resistance is very slow; it can take
months or even years for a stable drug-resistant line to
emerge. This limitation combined with the difﬁculties of the
in vitro culture technique (risk of contamination of cultures and
slow parasite growth) might explain why for many antimalarials
no stable resistant strains have been reported up to now.
A recent review has presented the methods and application of
the in vitro and in vivo selection of resistance.
19 In the current
paper, we have reviewed work carried out on the in vitro selection
of resistance for the past 30 years. This review has identiﬁed the
key parameters that are critical in the success of this process. We
propose strategies to streamline the in vitro selection of anti-
malarial drug resistance.
First and benchmark work
The ﬁrst work on the selection of P. falciparum in vitro was
reported in 1978 by Nguyen-Dinh and Trager
10 using the then
newly developed method of malaria culture, the Petri dish
method.
9 A Gambian (West Africa) strain (FCR3), whose growth
was completely inhibited at a concentration of 100 ng/mL
chloroquine, was grown in the presence of increasing chloro-
quine concentrations, starting from 10 ng/mL. After 15 cycles
(2 months), a parasite line that could grow in the presence of
100 ng/mL chloroquine was selected. This resistant phenotype
was stable, since the parasite could grow in drug-free medium
for several weeks without losing the selected phenotype. This
work was perceived as a landmark, as it opened up the possi-
bility that resistance could be selected against antimalarials
in vitro.
How to interpret the data on the in vitro
selection of resistance
We focused our review on publications that provided sufﬁcient
information on the in vitro selection experiment, including IC50
values (concentration that inhibits 50% of parasite growth), the
protocol used and stability information. We reviewed 16 publi-
cations and summarize the results in Table 1.
Right shift of the dose–response curve
In vitro, drug activity is assessed by growing the parasite in the
presence of various drug concentrations (serial dilution). The
equation for the parasite growth rate as a function of the drug
concentration generates a sigmoid dose–response curve, from
which are deduced IC50/IC90 values (inhibitory concentrations
that inhibit 50% or 90% of parasite growth). Resistance is
deﬁned by a right shift of the curve (Figure 1). The shape of
the shift can be parallel, with the same maximum parasite
killing effect (Emax) as the parent strain, or this shape could
change, with a reduced maximum parasite killing effect
(Figure 1).
20
We deﬁne the resistance index (Ri) as the ratio of the IC50 of
the resistant line to that of the parent strain. Thus, the higher the
Ri, the higher the level of resistance. However, a low Ri does not
necessarily mean a low level of resistance. As shown in Table 1,
Ri values can vary from 1 to .800. It is clear that an Ri of 100
indicates high-level resistance (found on strain W2 after drug
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392pressure of atovaquone and 5-ﬂuoro-orotate) (Table 1). An Ri of
,10 may indicate an intermediate resistance level. However, it is
interesting to note that the meﬂoquine-resistant parasite line
(from W2), which was used to identify the mechanism of meﬂo-
quine resistance, had an Ri of only 4.6 (Table 1), implying that
even a small right shift of the curve could be associated with
resistance.
21,22 In vivo, the relationship between the degree of
resistance and the resulting therapeutic responses is complex,
and depends on parameters such as the host immune response
and the pharmacokinetic and pharmacodynamic properties of
the drug.
68
Variation of in vitro assay data
There is interlaboratory (interassay) variation of IC50/IC90. The
culture conditions, mainly the initial parasitaemia, haematocrit,
the time of incubation, the timepoint when the label is added
(hypoxanthine for instance), the use of normal or substitute
serum and the gas mixture composition, have been singled out
as inﬂuencing the test.
23,24 A right shift as a result of interassay
variation could be wrongly interpreted as reﬂecting resistance.
Therefore, any right shift is considered valid only if all in vitro
culture parasite parameters are maintained constant.
Instability of the resistant phenotype
The resistant phenotype is stable when it remains unchanged
after growing parasites in drug-free medium. In Table 1, in
studies in which stability was reported, parasite lines remained
resistant when grown in the absence of the drug during time
periods varying from 2 weeks to 1 year and, in two studies, resist-
ance remained unchanged after parasite cryopreservation. The
unstable phenotypes could be associated with reduced parasite
ﬁtness, explaining why, once drug pressure is removed, the phe-
notype reverts to normal. For instance, a recent study has shown
that parasites grown under meﬂoquine pressure expressed mul-
tiple pfmdr1 copy numbers and that these parasites had a sig-
niﬁcantly decreased survival ﬁtness compared with parasites
with a single pfmdr1 copy number.
25
Existence of more than one parasite population during
drug pressure
We computed the ratio of the highest drug concentration at
which the parasite grew normally during the selection
process with the parasite drug IC50 after drug selection
(highest drug concentration tested/IC50, Table 1). This ratio is
expected to be ,1, since it represents the ratio of a subinhibi-
tory concentration (thus, ,IC50) divided by the IC50.I n7 / 1 5
strains, this ratio was  1.1. The most striking data were
observed with W2mef on meﬂoquine,
26 showing a ratio
.148. This indicates that this parasite line could grow in the
presence of a drug concentration 148 times higher than its
own IC50. This led to the discovery that, in fact, there were
two parasite populations with different IC50 values—one with
a lower value, which corresponds to the dominant population,
and another minor population, with a higher IC50 value. The
second population is the one that persists when parasites are
cultured in the presence of high drug concentrations. When
determining IC50 values, drug pressure is removed and,
because of the ﬁtness disadvantage conferred by the
drug-resistant phenotype, the minor population is replaced by
the dominant and drug-susceptible one, reﬂecting low IC50
values. Since the determination of IC50 v a l u e si sb a s e do nt h e
use of a ‘monophasic’ drug–response curve, only one IC50 is
obtained, which represents the dominant population.
However, the presence of two populations in a mixture can
be identiﬁed using a ‘biphasic’ drug–response curve.
26
Figure 2 summarizes the graphic representation of the use of
a biphasic drug–response curve leading to the identiﬁcation
of two populations.
26 Thus, a ratio of .1 indicates the exist-
ence of at least two parasite populations and selection
emerges on the backdrop of the minor population, which
gradually becomes dominant as the drug-pressure experiment
continues.
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Figure 1. Drug–response as a function of the concentration. Any right
shift of the curve denotes an increase in the IC50 and, thus, the
resistance. The shift can be parallel or the shape of the curve and the
maximum effect (Emax) could change. Reproduced from Trends in
Parasitology, 18(10), White NJ, The assessment of antimalarial drug
efﬁcacy, 458–64, 2002, with permission from Elsevier.
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Figure 2. Dose concentration–response of an in vitro-selected
meﬂoquine (MFQ)-resistant line that could grow in the presence of
.1200 ng/mL meﬂoquine. The dose–response was analysed using a
modiﬁcation of the logistic logarithmic function that permits evaluation
of a biphasic concentration–response relationship. Two parasite
populations with different IC50s can be deﬁned from this graph, yet the
use of a monophasic concentration–response would have generated
one single IC50 (inhibitory concentration that kills 50% of parasites).
Reproduced, with permission, from Peel et al. (Figure 4b).
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JACHow useful has in vitro resistance been?
The main objective of inducing in vitro resistance is to generate
parasite lines that can be used to study the mechanism of resist-
ance. How much has already been done with the P. falciparum
cell lines that were selected in vitro?
Meﬂoquine and chloroquine
The ﬁrst selection of in vitro meﬂoquine resistance was carried
out in the early 1980s.
27,28 In 1988, Oduola et al.
21 selected
the meﬂoquine-resistant strain W2mef, from the parent strain
W2. The analysis of P-glycoprotein pfmdr1 between W2 and
W2mef led to the discovery of the association between ampliﬁ-
cation of this gene and meﬂoquine resistance.
22 Thereafter, the
WEHI group (Walter and Eliza Hall Institute) induced meﬂoquine
resistance against the K1 strain and further against the W2mef
line, and conﬁrmed the involvement of pfmdr1 in meﬂoquine
resistance.
29 Since then, these ﬁndings have been supported in
ﬁeld isolates
30–33 and in rodent malaria.
5
The aforementioned studies and the one by Barnes et al.
34 on
the selection of chloroquine resistance (Table 1) showed the
existence of an inverse relationship between the pfmdr1 copy
number (meﬂoquine resistance) and chloroquine susceptibility.
This prompted further investigations into pfmdr1 polymorphism
in relation to chloroquine susceptibility. Several single nucleotide
polymorphisms in this gene have been associated with chloro-
quine resistance and it has now been established that this
gene plays an ancillary role in chloroquine resistance, the key
gene being pfcrt.
30,35–37
The use of in vitro-selected chloroquine-resistant parasite
lines has also led to a better understanding of the mechanisms
of chloroquine resistance. Chloroquine resistance was induced in
the Sudanese strain 106/1.
38 This strain contains seven
mutations associated with chloroquine resistance in pfcrt (at
codons 74, 75, 220, 271 and 371), but the key one, at codon
76, is wild type (lysine), while chloroquine-resistant isolates
have threonine at this codon. This strain was chloroquine suscep-
tible. By subjecting it to chloroquine pressure for 2 months, a
chloroquine-resistant line was selected. Subsequent genetic
analyses demonstrated that this selected chloroquine-resistant
phenotype was associated with the presence of a mutation at
pfcrt codon 76 (from lysine to isoleucine or asparagine).
Though this mutated amino acid was not threonine, this study
conﬁrmed the critical role of the mutation at codon 76 in chlor-
oquine resistance.
The HB3 strain was used to select chloroquine resistance and
further analysis demonstrated the existence of DNA ampliﬁca-
tion in chromosomes 3 and 12 in this parasite line.
39 It is inter-
esting to note that neither pfmdr1 nor pfcrt are located on
chromosomes 3 or 12. Since the mechanism of chloroquine
resistance is known to be multifactorial, other genes might be
involved; however, no further studies have been carried out on
these cell lines.
Pyrimethamine
Banyal and Inselburg
40 selected FCR3 parasite lines resistant to
pyrimethamine. This phenotype was found to be associated
with DNA ampliﬁcation on chromosome 4 in a region
corresponding to the dihydrofolate reductase–thymidine
synthase gene (dhfr-ts).
41,42 It was also found that these para-
site lines harbour a point mutation at codon 223 of the dhfr
domain,
42 in line with the role of this gene in pyrimethamine
resistance.
43–45
Atovaquone
This drug has been combined with proguanil to form Malarone
w,
one of the most potent antimalarial prophylactic agents. Atova-
quone binds to cytochrome b (Cyt b), leading to the inhibition of
mitochondrial electron transfer, and mutation in Cyt b has been
associated with atovaquone resistance in vivo.
46 Using drug
pressure on the K1 strain, Korsinczky et al.
46 selected parasite
lines resistant to atovaquone, with Ri varying from 76- to
837-fold. Sequencing of the Cyt b gene of these parasites
showed point mutations at codons 275, 272, 280, 281, 284
and 280, and these codons are located in the binding pocket
of atovaquone to Cyt b.
46 Interestingly, the mutation at 268,
which is commonly found in atovaquone-resistant ﬁeld isolates,
is also located in this binding pocket.
47–49
BMS-388891
This compound is an inhibitor of protein farnesyl transferase
(PFT), which catalyses the transfer of the farnesyl group to the
C-terminus of a speciﬁc set of proteins, including those that
are essential in cell multiplication, and the blockade of this farne-
sylation is associated with cell death.
50 Inhibition of the PFT
enzyme is a good drug target against malaria, and many inhibi-
tors have been synthesized and evaluated as potential antima-
larials.
50–52 Eastman et al.
51 induced resistance to an inhibitor
of PFT, BMS-388891, by culturing the Dd2 strain in the presence
of continuous drug pressure. Within 80 days, a line with a 12-fold
decreased activity was selected and genetic analyses have
shown the existence of a point mutation at codon 837 of PFT.
Thus, polymorphism in the PFT enzyme could be associated
with in vivo resistance to inhibitors of PFT in the clinical setting.
Azithromycin
The macrolide azithromycin, along with erythromycin, has
proved to be active against P. falciparum, and several clinical
trials of azithromycin and erythromycin alone or in combination
with chloroquine, quinine or artesunate have been conducted.
These macrolide agents are promising antimalarials, especially
in the treatment of malaria in pregnancy.
53–58 An azithromycin-
pressure experiment on Dd2 and 7G8 strains led to the selection
of resistant lines within 21 days, and these lines showed cross-
resistance to erythromycin.
59 This phenotype was associated
with point mutations in P. falciparum apicoplast-encoded riboso-
mal protein L4 (pfRpL4), one of the proteins that form the 50S
ribosomal subunit,
59 in line with the macrolide resistance mech-
anism in bacteria.
59 Though azithromycin and erythromycin are
still experimental drugs, the use of laboratory-induced resistant
lines has led to the identiﬁcation of drug resistance genes
before these drugs enter clinical use. The ease with which in
vitro resistance to macrolides has been selected in vitro may
indicate that the selection and spread of in vivo resistance may
be rapid. This drug is still in clinical evaluation against malaria
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conﬁrmed in vivo.
This information clearly demonstrates the value of
drug-resistant parasite lines selected in vitro. For instance,
pfmdr1, one of the genes central to resistance to quinoline or
quinoline-related drugs, was identiﬁed using in vitro-selected
drug resistance parasite lines. The use of the same approach
has led to the conﬁrmation of pyrimethamine and chloroquine
mechanisms of resistance. Work on the macrolide azithromycin
and an inhibitor of PFT has demonstrated that it is possible to
understand the mechanism of drug resistance before the drug
is used in the clinical setting, and before resistant parasites are
found in the ﬁeld.
51,59 In theory, the same could be achieved
with any other antimalarial drugs.
Are there strains more prone to becoming drug
resistant?
Early reports using murine malaria indicate that a strain resistant
to one drug is more amenable to give rise to resistant lines to
another drug, compared with strains that are fully drug suscep-
tible. Pyrimethamine- and chloroquine-resistant parasites were
more easily generated from drug-resistant strains than from
drug-susceptible ones in P. chabaudi and P. vinckei.
60–62Evidence
that the same phenomenon prevails in P. falciparum has been
provided by Rathod’s group.
63 They induced resistance to atova-
quone and 5-ﬂuoro-orotate against the multidrug-resistant
strain W2 (cycloguanil, pyrimethamine and sulfadoxine resist-
ant), FCR3 (pyrimethamine and cycloguanil resistant), HB3 (pyr-
imethamine resistant), 3D7 (sulfadoxine resistant) and the fully
drug-susceptible D6. They demonstrated that W2 was more
prone to generate drug-resistant parasite lines than FCR3 and
that the latter was more prone than 3D7. Not a single resistant
line was obtained from the fully drug-susceptible D6. The W2
strain acquired resistance to these drugs with a frequency 10-
to 1000-fold higher than the frequency in other strains. This
phenomenon was named ‘accelerated resistance to multidrug
(ARMD)’ and is different to the known multidrug-resistant pheno-
type.
63 ARMD is characterized by the ability of a strain to gener-
ate a drug-resistant clone when put under drug pressure. This
results from the high mutation rate during parasite multipli-
cation. The low efﬁciency of the mechanisms of DNA repair has
been proffered as one of the factors that contribute to this
ARMD phenotype.
19,64
For instance, HB3 is susceptible to almost all antimalarial
drugs, except pyrimethamine. It has one single point mutation
at codon 108 in dhfr
65 and, thus, has a low level of pyrimetha-
mine resistance. As shown in Table 1, chloroquine drug pressure
for 30 months gave rise to a line with an Ri of only 1.64, a value
that is among the lowest in Table 1. On the other hand, high level
of drug-resistant phenotype does not necessarily imply a higher
ability to generate drug-resistant lines. This is the case for
W2mef. This parasite line is resistant to many antimalarials
and is, thus, more prone to generate resistant clones (as dis-
cussed earlier). However, it could not generate resistant clones
when subjected to meﬂoquine drug pressure (Ri,2, see
Table 1).
26,29 The reason could be that it was already meﬂoquine
resistant, as a result of pfmdr1 being overexpressed. W2mef,
therefore, needed to develop new and additional mechanisms
to cope with the higher meﬂoquine concentration, explaining,
at least partially, the difﬁculties in generating stable clones
with higher meﬂoquine resistance. This is supported by the fact
that, in vivo, no new mechanisms of meﬂoquine resistance
have been reported other than pfmdr1 ampliﬁcation. Thus, the
ability of a parasite to generate resistant lines will vary from
one strain to another.
What should be considered when designing
an ‘in vitro drug selection’ study?
The following are critical parameters that have to be considered
when setting up the experiment.
Initial strains
Strains are different; there are those that are more prone to gen-
erate resistant parasite lines than others, and these are called
ARMD strains (see previous section). Thus, in vitro selection for
resistance should focus on drug-resistant strains/isolates.
Initial parasitaemia
One of the key parameters in the success of these experiments is
the initial parasitaemia. Work in animals has shown that the
higher the initial parasitaemias, the higher is the chance of
selecting drug-resistant mutants. For instance, Ramakrishnan
et al.
66 could select sulfadiazine resistance in P. berghei in mice
at 10% parasitaemia, but failed to do so at 1%. The most inter-
esting evidence was provided in humans, where it was shown
that the chance of developing pyrimethamine resistance after
a single-dose treatment was associated with the size of the
parasite population.
67
Genetic events that confer de novo drug resistance (gene
point mutations or copy number variations) are spontaneous
and rare, and are drug independent. In vitro, parasites undergo
mitotic nuclear division exclusively. Thus, the chance of obtaining
a mutant strain that will confer drug resistance will be a function
of the number of mitotic events and, thus, the size of the para-
site population.
The generation of de novo resistance is also dependent upon
the rate at which parasites generate drug-resistant clones. Since
this rate, the per-parasite resistance frequency (PRF), varies
depending on the mutation (or the gene), different drugs will
have different rates; if resistance involves one single gene, the
PRF is likely to be higher than when resistance is multifactorial.
For instance, in vivo, the PRF for pyrimethamine, atovaquone
and meﬂoquine has been estimated to be 10
11,1 0
12 and 10
14,
respectively; chloroquine has been proposed to be 10
19; and
values ,10
18 have been proposed for artemisinin.
68 Interest-
ingly, in general, PRF rates are found to be higher in vivo, e.g.
atovaquone-resistant mutants arise at a frequency of 1 in
10
5,
63 and the rate with meﬂoquine is 1 in 10
8 and 1 in 10
13
when resistance is associated with one and two/three pfmdr1
copy numbers, respectively.
25 Thus, different drugs will have a
different chance to encounter a drug-resistant clone in vitro.
There are 5 10
16–5 10
17 circulating parasites in the
human population.
2 If such numbers of parasites could be put
into a ﬂask to induce in vitro resistance, one could expect that
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theory, resistant strains would already be present in the popu-
lation. Generally, cultures are carried out in small ﬂasks
(15 mL) containing 5 mL of the culture suspension [2% haema-
tocrit, equivalent to 100 mL of red blood cells (RBCs)]. Assuming
that 10% parasitaemia could be reached after culture, only 10
8
infected RBCs could be obtained using such ﬂasks.
For drugs such as atovaquone with a higher PRF, chances are
high that a resistant clone will emerge after some mitotic
events with a starting parasitaemia of 10
8; thus, under these con-
ditions, atovaquone resistance would be relatively easy to select,
as shown in Table 1. On the other hand, for drugs with a low
PRF, such as artemisinin, a starting parasitaemia of 10
8 will not
be favourable to the selection of resistance. Thus, current exper-
imental conditions do not favour the emergence of resistant
mutants against drugs with a low PRF. Thus, experiments should
be carried out under conditions where a higher parasite number
could be used. There should not be a limitation of parasite
number, apartfromthatimposed bythe experimental conditions.
Use of current multidrug-resistant strains
One of the characteristics of ARMD strains is that they are multi-
drug resistant. The more drugs that parasites have been exposed
to, the higher their chance of harbouring an ARMD phenotype.
The current strains used in selection of resistance studies were
collected 20–30 years ago. For instance, W2, the most com-
monly used strains to induce resistance, were collected in the
1970s. Since then, parasites have been exposed to new antima-
larials. It is reasonable to state that the current multidrug strains
are more prone to generate resistance than strains collected
30 years ago. Consequently, the selection of resistance should
also include contemporary parasite strains to maximize the
chance of obtaining drug-resistant clones. Parasites from
malaria-endemic areas where drug resistance is high, for
instance South East Asia, should be considered. Another
approach would be to use genetically modiﬁed parasites that
are more prone to generate new mutants. Such parasites could
be those with impaired DNA repair mechanisms;
64 however,
they are not available yet.
Time of experiment
The success of the selection of resistance depends on the length
of the experimental time period. The longer the selection of
resistance takes, the higher the chance of obtaining resistant
lines. In theory, for any drug, resistance will eventually emerge
when given sufﬁcient time. The question is therefore how long
the process should take or when to stop.
The process can stop for two reasons. The ﬁrst could be that
parasites have reached the limit of acceptable concentration
beyond which they can no longer grow. Alternative drug-free
and short exposures to high drug concentrations could overcome
this limitation.
26 The second reason, which is more common, is
that the process is stopped by the experimenter. For instance,
two experiments in which the authors failed to select artesunate
(an artemisinin derivative) and ferroquine resistance were
stopped within 1 month of drug pressure.
6,69 As we discussed,
for a drug such as artemisinin, which has the lowest PRF, it
would be surprising that resistant parasites would emerge
in vitro within 1–2 months. Thus, it is reasonable to expect
that more time, even in terms of years, would be required to
induce in vitro resistance against this drug. It is therefore critical
that the experimenter bears these considerations in mind when
setting up drug resistance studies. For instance, Aly et al.
70
selected a parasite line resistant to the endoperoxide N-89
after 2 years of continuous drug pressure. However, this
N-89-resistant strain was susceptible to the endoperoxide arte-
misinin, indicating that the mechanisms of resistance between
these drugs are different.
Conclusions
Thirty years ago, the ﬁrst report that chloroquine resistance could
be induced in vitro heralded a new era with the expectation that
antimalarial-resistant parasite lines could be obtained, allowing
study of the mechanism of resistance before drugs reached
clinical use. Although the approach has been used to discover
and/orconﬁrmthemechanismofresistancetovariousantimalar-
ials, including meﬂoquine, chloroquine and pyrimethamine, it is
surprising to note that for important drugs such as artemisinin
or lumefantrine, which now form the backbone of malaria treat-
ment, no well-characterized resistant parasite lines exist, limiting
investigations on their mechanism of resistance. Yet the use of
an in vitro system could allow the selection of resistant parasites
against any antimalarials. Attempts have been made to select
resistancetoartemisinininvitro,butinvain.Theselectionofresist-
ance is challenging and time consuming. Our review of the litera-
tureshowsthatstrategiesexisttostreamlinethisprocess.Withthe
development of new molecular technologies, such as Solexa Illu-
mina and 454-sequencing, which allow high-throughput DNA
sequencing and whole transcriptome analysis, it is now possible
to study drug resistance mechanisms by exploring the parasite
whole genome variation at a relatively low cost and in a short
time period. However, the challenge remains the generation of
drug-resistant parasite lines.
Acknowledgements
We thank the Director of the Kenya Medical Research Institute for
permission to publish this review. We also thank Professor Nick White
for helpful comments.
Funding
This study was supported by the European Developing Countries Clinical
Trials Partnership (EDCTP) and The Wellcome Trust WT077092 and
WT084538.
Transparency declarations
None to declare.
References
1 White NJ. Qinghaosu (artemisinin): the price of success. Science 2008;
320: 330–4.
2 White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113:
1084–92.
Review
3963 Peters W. Chemotherapy and Drug Resistance in Malaria. London:
Academic Press, 1987.
4 Afonso A, Hunt P, Cheesman S et al. Malaria parasites can develop
stable resistance to artemisinin but lack mutations in candidate genes
atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2þ
ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother 2006; 50:
480–9.
5 Carlton JM, Hayton K, Cravo PV et al. Of mice and malaria mutants:
unravelling the genetics of drug resistance using rodent malaria
models. Trends Parasitol 2001; 17: 236–42.
6 Hunt P, Afonso A, Creasey A et al. Gene encoding a deubiquitinating
enzyme is mutated in artesunate- and chloroquine-resistant rodent
malaria parasites. Mol Microbiol 2007; 65: 27–40.
7 Hunt P, Cravo PV, Donleavy P et al. Chloroquine resistance in
Plasmodium chabaudi: are chloroquine-resistance transporter (crt) and
multi-drug resistance (mdr1) orthologues involved? Mol Biochem
Parasitol 2004; 133: 27–35.
8 Hunt P, Martinelli A, Fawcett R et al. Gene synteny and chloroquine
resistance in Plasmodium chabaudi. Mol Biochem Parasitol 2004; 136:
157–64.
9 Trager W, Jensen JB. Human malaria parasites in continuous culture.
Science 1976; 193: 673–5.
10 Nguyen-Dinh P, Trager W. Chloroquine resistance produced in vitro in
an African strain of human malaria. Science 1978; 200: 1397–8.
11 Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the
treatment of uncomplicated falciparum malaria. Expert Opin
Pharmacother 2007; 8: 75–94.
12 Myint HY, Ashley EA, Day NP et al. Efﬁcacy and safety of
dihydroartemisinin–piperaquine. Trans R Soc Trop Med Hyg 2007; 101:
858–66.
13 Ramharter M, Kurth F, Schreier AC et al. Fixed-dose pyronaridine–
artesunate combination for treatment of uncomplicated falciparum
malaria in pediatric patients in Gabon. J Infect Dis 2008; 198:
911–9.
14 Checkley AM, Whitty CJ. Artesunate, artemether or quinine in severe
Plasmodium falciparum malaria? Expert Rev Anti Infect Ther 2007; 5:
199–204.
15 Dondorp A, Nosten F, Stepniewska K et al. Artesunate versus quinine
for treatment of severe falciparum malaria: a randomised trial. Lancet
2005; 366: 717–25.
16 Jones KL, Donegan S, Lalloo DG. Artesunate versus quinine for
treating severe malaria. Cochrane Database Syst Rev 2007; issue 4:
CD005967.
17 Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium
falciparum malaria. N Engl J Med 2009; 361: 455–67.
18 Jambou R, Legrand E, Niang M et al. Resistance of Plasmodium
falciparum ﬁeld isolates to in-vitro artemether and point mutations of
the SERCA-type PfATPase6. Lancet 2005; 366: 1960–3.
19 Witkowski B, Berry A, Benoit-Vical F. Resistance to antimalarial
compounds: methods and applications. Drug Resist Updat 2009; 12:
42–50.
20 White NJ. The assessment of antimalarial drug efﬁcacy. Trends
Parasitol 2002; 18: 458–64.
21 Oduola AM, Milhous WK, Weatherly NF et al. Plasmodium falciparum:
induction of resistance to meﬂoquine in cloned strains by continuous
drug exposure in vitro. Exp Parasitol 1988; 67: 354–60.
22 Wilson CM, Serrano AE, Wasley A et al. Ampliﬁcation of a gene related
to mammalian mdr genes in drug-resistant Plasmodium falciparum.
Science 1989; 244: 1184–6.
23 Basco LK. Molecular epidemiology of malaria in Cameroon. XX.
Experimental studies on various factors of in vitro drug sensitivity
assays using fresh isolates of Plasmodium falciparum. Am J Trop Med
Hyg 2004; 70: 474–80.
24 Briolant S, Parola P, Fusai Tet al. Inﬂuence of oxygen on asexual blood
cycle and susceptibility of Plasmodium falciparum to chloroquine:
requirement of a standardized in vitro assay. Malar J 2007; 6: 44.
25 Preechapornkul P, Imwong M, Chotivanich K et al. Plasmodium
falciparum pfmdr1 ampliﬁcation, meﬂoquine resistance, and parasite
ﬁtness. Antimicrob Agents Chemother 2009; 53: 1509–15.
26 Peel SA, Merritt SC, Handy J et al. Derivation of highly
meﬂoquine-resistant lines from Plasmodium falciparum in vitro. Am J
Trop Med Hyg 1993; 48: 385–97.
27 Brockelman CR, Monkolkeha S, Tanariya P. Decrease in susceptibility of
Plasmodium falciparum to meﬂoquine in continuous culture. Bull World
Health Organ 1981; 59: 249–52.
28 Lambros C, Notsch JD. Plasmodium falciparum: meﬂoquine resistance
produced in vitro. Bull World Health Organ 1984; 62: 433–8.
29 Cowman AF, Galatis D, Thompson JK. Selection for meﬂoquine
resistance in Plasmodium falciparum is linked to ampliﬁcation of the
pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc
Natl Acad Sci USA 1994; 91: 1143–7.
30 Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to
antimalarial drug-resistance. Acta Trop 2005; 94: 181–90.
31 Price RN, Cassar C, Brockman A et al. The pfmdr1 gene is associated
with a multidrug-resistant phenotype in Plasmodium falciparum from
the western border of Thailand. Antimicrob Agents Chemother 1999;
43: 2943–9.
32 Price RN, Uhlemann AC, Brockman A et al. Meﬂoquine resistance in
Plasmodium falciparum and increased pfmdr1 gene copy number.
Lancet 2004; 364: 438–47.
33 Uhlemann AC, McGready R, Ashley EA et al. Intrahost selection of
Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on
the northwestern border of Thailand. J Infect Dis 2007; 195: 134–41.
34 Barnes DA, Foote SJ, Galatis D et al. Selection for high-level
chloroquine resistance results in deampliﬁcation of the pfmdr1 gene
and increased sensitivity to meﬂoquine in Plasmodium falciparum.
EMBO J 1992; 11: 3067–75.
35 Sanchez CP, Stein WD, Lanzer M. Is PfCRT a channel or a carrier? Two
competing models explaining chloroquine resistance in Plasmodium
falciparum. Trends Parasitol 2007; 23: 332–9.
36 Valderramos SG, Fidock DA. Transporters involved in resistance to
antimalarial drugs. Trends Pharmacol Sci 2006; 27: 594–601.
37 Ekland EH, Fidock DA. Advances in understanding the genetic basis of
antimalarial drug resistance. Curr Opin Microbiol 2007; 10: 363–70.
38 Cooper RA, Ferdig MT, Su XZ et al. Alternative mutations at position 76
of the vacuolar transmembrane protein PfCRT are associated with
chloroquine resistance and unique stereospeciﬁc quinine and quinidine
responses in Plasmodium falciparum. Mol Pharmacol 2002; 61: 35–42.
39 Lim AS, Cowman AF. Plasmodium falciparum: chloroquine selection of
a cloned line and DNA rearrangements. Exp Parasitol 1996; 83: 283–94.
40 Banyal HS, Inselburg J. Plasmodium falciparum: induction, selection,
and characterization of pyrimethamine-resistant mutants. Exp Parasitol
1986; 62: 61–70.
41 Inselburg J, Bzik DJ, Horii T. Pyrimethamine resistant Plasmodium
falciparum: overproduction of dihydrofolate reductase by a gene
duplication. Mol Biochem Parasitol 1987; 26: 121–34.
42 Tanaka M, Gu HM, Bzik DJ et al. Mutant dihydrofolate reductase–
thymidylate synthase genes in pyrimethamine-resistant Plasmodium
Review
397
JACfalciparum with polymorphic chromosome duplications. Mol Biochem
Parasitol 1990; 42: 83–91.
43 Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites
to antifolates. Pharmacol Rev 2005; 57: 117–45.
44 Nzila A. The past, present and future of antifolates in the treatment of
Plasmodium falciparum infection. J Antimicrob Chemother 2006; 57:
1043–54.
45 Hawkins VN, Joshi H, Rungsihirunrat K et al. Antifolates can have a
role in the treatment of Plasmodium vivax. Trends Parasitol 2007; 23:
213–22.
46 Korsinczky M, Chen N, Kotecka B et al. Mutations in Plasmodium
falciparum cytochrome b that are associated with atovaquone
resistance are located at a putative drug-binding site. Antimicrob
Agents Chemother 2000; 44: 2100–8.
47 Berry A, Senescau A, Lelievre J et al. Prevalence of Plasmodium
falciparum cytochrome b gene mutations in isolates imported from
Africa, and implications for atovaquone resistance. Trans R Soc Trop
Med Hyg 2006; 100: 986–8.
48 Musset L, Bouchaud O, Matheron S et al. Clinical atovaquone–
proguanil resistance of Plasmodium falciparum associated with
cytochrome b codon 268 mutations. Microbes Infect 2006; 8: 2599–604.
49 Pimentel S, Nogueira F, Benchimol C et al. Detection of atovaquone–
proguanil resistance conferring mutations in Plasmodium falciparum
cytochrome b gene in Luanda, Angola. Malar J 2006; 5: 30.
50 Buckner FS, Eastman RT, Yokoyama K et al. Protein farnesyl
transferase inhibitors for the treatment of malaria and African
trypanosomiasis. Curr Opin Investig Drugs 2005; 6: 791–7.
51 Eastman RT, White J, Hucke O et al. Resistance to a protein
farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem
2005; 280: 13554–9.
52 Olepu S, Suryadevara PK, Rivas K et al. 2-Oxo-tetrahydro-
1,8-naphthyridines as selective inhibitors of malarial protein
farnesyltransferase and as anti-malarials. Bioorg Med Chem Lett 2008;
18: 494–7.
53 Noedl H, Krudsood S, Leowattana Wet al. In vitro antimalarial activity
of azithromycin, artesunate, and quinine in combination and correlation
with clinical outcome. Antimicrob Agents Chemother 2007; 51: 651–6.
54 Kalilani L, Mofolo I, Chaponda M et al. A randomized controlled pilot
trial of azithromycin or artesunate added to sulfadoxine–pyrimethamine
as treatment for malaria in pregnant women. PLoS ONE 2007; 2: e1166.
55 Noedl H, Krudsood S, Chalermratana K et al. Azithromycin
combination therapy with artesunate or quinine for the treatment of
uncomplicated Plasmodium falciparum malaria in adults: a randomized,
phase 2 clinical trial in Thailand. Clin Infect Dis 2006; 43: 1264–71.
56 Miller RS, Wongsrichanalai C, Buathong N et al. Effective treatment of
uncomplicated Plasmodium falciparum malaria with azithromycin–
quinine combinations: a randomized, dose-ranging study. Am J Trop
Med Hyg 2006; 74: 401–6.
57 Dunne MW, Singh N, Shukla M et al. A double-blind, randomized study
of azithromycin compared to chloroquine for the treatment of
Plasmodium vivax malaria in India. Am J Trop Med Hyg 2005; 73:
1108–11.
58 Dunne MW, Singh N, Shukla M et al. A multicenter study of
azithromycin, alone and in combination with chloroquine, for the
treatment of acute uncomplicated Plasmodium falciparum malaria in
India. J Infect Dis 2005; 191: 1582–8.
59 Sidhu AB, Sun Q, Nkrumah LJ et al. In vitro efﬁcacy, resistance
selection, and structural modeling studies implicate the malarial
parasite apicoplast as the target of azithromycin. J Biol Chem 2007;
282: 2494–504.
60 Peters W, Porter M. The chemotherapy of rodent malaria, XXVI. The
potential value of WR 122,455 (a 9-phenanthrenemethanol) against
drug-resistant malaria parasites. Ann Trop Med Parasitol 1976; 70:
271–81.
61 Powers KG, Jacobs RL, Good WC et al. Plasmodium vinckei: production
of chloroquine-resistant strain. Exp Parasitol 1969; 26: 193–202.
62 Rosario VE. Genetics of chloroquine resistance in malaria parasites.
Nature 1976; 261: 585–6.
63 Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug
resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997; 94:
9389–93.
64 Trotta RF, Brown ML, Terrell JC et al. Defective DNA repair as a
potential mechanism for the rapid development of drug resistance in
Plasmodium falciparum. Biochemistry 2004; 43: 4885–91.
65 Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation
in dihydrofolate reductase–thymidylate synthase confers resistance to
pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 1988; 85:
9114–8.
66 Ramakrishnan SP, Prakash S, Chowdhury DS et al. Studies on
Plasmodium berghei Vincke and Lips, 1948. XXIX. The size of parasite
population and its relation to the selection of a strain resistant to
sulphadiazine. Indian J Malariol 1961; 15: 95–106.
67 Martin DC, Arnold JD. The effect of parasite populations on the
curative action of pyrimethamine. Trans R Soc Trop Med Hyg 1968; 62:
379–84.
68 White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant
malaria parasites. Proc Biol Sci 2003; 270: 545–54.
69 Daher W, Biot C, Fandeur T et al. Assessment of Plasmodium
falciparum resistance to ferroquine (SSR97193) in ﬁeld isolates and in
W2 strain under pressure. Malar J 2006; 5: 11.
70 Aly NS, Hiramoto A, Sanai H et al. Proteome analysis of new
antimalarial endoperoxide against Plasmodium falciparum. Parasitol Res
2007; 100: 1119–24.
71 Nkrumah LJ, Riegelhaupt PM, Moura P et al. Probing the multifactorial
basis of Plasmodium falciparum quinine resistance: evidence for a
strain-speciﬁc contribution of the sodium–proton exchanger PfNHE. Mol
Biochem Parasitol 2009; 165: 122–31.
Review
398